芪苈强心胶囊对重组人血管内皮抑素联合化疗所致心脏毒性保护作用的研究  

Observation of Qiliqiangxin capsule on the inhibition of cardiotoxicity induced by recombinant human endostatin combined with actinotherapy

作　　者：刘永欣[1] 赵晓晖[2] 孟存良[1] 刘会娟[3] 

机构地区：[1]河北省人民医院心脏二科,河北石家庄050051 [2]河北省人民医院肿瘤二科,河北石家庄050051 [3]河北省博野县医院肿瘤科,河北保定071300

出　　处：《河北中医》2013年第4期576-577,共2页Hebei Journal of Traditional Chinese Medicine

摘　　要：目的观察芪苈强心胶囊对重组人血管内皮抑素联合化疗所致心脏毒性的保护作用。方法将19例肿瘤患者随机分为2组。治疗组8例予重组人血管内皮抑素联合化疗同时加芪苈强心胶囊,自化疗前1 d开始口服1.2 g,每日3次,对照组11例予重组人血管内皮抑素联合化疗,不予芪苈强心胶囊治疗,3周为1个周期。分别于第1、2化疗周期开始前,第1、2化疗周期后,检测患者肌酸激酶同工酶(CK-MB)、肌钙蛋白T(cTnT)变化,并进行统计学分析。结果 CK-MB于第2个化疗周期后,2组比较差异有统计学意义(P<0.05)。cTnT于第1化疗周期后、第2化疗周期前、第2个化疗周期后,2组比较差异均有统计学意义(P<0.05)。结论芪苈强心胶囊对重组人血管内皮抑素联合化疗所致心脏毒性有保护作用。Objective To observe the effects of Qiliqiangxin capsule on the inhibition of cardiotoxicity in- duced by recombinant human endostatin combined with actinotherapy. Methods 19 patients with cancer were en- rolled in the study and randomly divided into trial group （8 cases） and control group （11 cases）. In the trial group, the patients received Qiliqiangxin capsule combined with endostar and actinotherapy, Qiliqiangxin capsule were ad- ministered orally （1.2g, Tid, 0.3g/capsule） before 1 day from the first day of actinotherapy. In the control group, the patients received only with endostar and chemotherapy at the same dosage. Three weeks were regarded as one cycle in two groups. Serum levels of myocardial markers CK - MB and cTnT were measured in all the patients before and af- ter each chemotherapy cycle respectively. Results CK - MB level was found statistically difference in two groups af- ter the second chemotherapy cycle, cTnT level was found statistically difference in two groups after the first chemother- apy cycle, before and after the second chemotherapy cycle respectively. Conclusion Qiliqiangxin capsule can inhibit cardiotoxicity induced by recombinant human endostatin combined with actinotherapy.

关 键 词：胶囊 肿瘤 药物疗法 内皮抑素类 心脏病 化学诱导心血管药物(中药) 

分 类 号：R541.5[医药卫生—心血管疾病] R541.053[医药卫生—内科学]